Related Experiment Video

Updated: Sep 28, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF)

Wendy A Gattis1, Christopher M O'Connor, Mihai Gheorghiade

  • 1Department of Medicine, Divisions of Clinical Pharmacology and Cardiology, Duke University Medical Center, Durham, North Carolina, USA.

Reviews in Cardiovascular Medicine
|November 26, 2002
PubMed

Insights

Initiating carvedilol before hospital discharge significantly improves beta-blocker use in heart failure patients. This strategy enhances adherence to guidelines and promotes long-term medication use for better outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Beta-blocker underutilization for heart failure (HF) persists in the US despite guideline recommendations.
  • Current guidelines often delay beta-blocker initiation post-hospitalization for HF.
  • Evidence-based medicine adoption in HF management requires improvement.

Purpose of the Study:

  • To assess the safety and efficacy of initiating carvedilol before hospital discharge in HF patients.
  • To determine if pre-discharge initiation improves 60-day beta-blocker use compared to usual care.
  • To explore strategies for enhancing evidence-based pharmacotherapy in clinical practice.

Main Methods:

  • The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) is a multicenter, open-label trial.
  • 375 HF patients were randomized to either pre-discharge carvedilol initiation or usual care.
  • The primary endpoint was the proportion of patients on any beta-blocker at 60 days post-discharge.

Main Results:

  • In-hospital initiation of carvedilol was found to be safe and effective.
  • This strategy significantly increased the number of patients treated with beta-blockers at 60 days.
  • The study demonstrated improved adherence to guideline-recommended therapy.

Conclusions:

  • Initiating beta-blocker therapy prior to hospital discharge is a viable strategy to improve long-term medication use in heart failure.
  • This approach helps bridge the gap between guideline recommendations and clinical practice.
  • Optimizing beta-blocker therapy can reduce morbidity and mortality in heart failure patients.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...